(PDF) P3.13-04 Lorlatinib in Anaplastic Lymphoma Kinase and

P3.13-04 Lorlatinib in Anaplastic Lymphoma Kinase and Proto-Oncogene Tyrosine-Protein Kinase ROS-Positive Non-Small Cell Lung Cancer

Journal of Thoracic Oncology - United States

doi 10.1016/j.jtho.2018.08.1844

Full Text

Abstract

Available in full text

Categories

Respiratory Medicine

Date

October 1, 2018

Authors

J. Minnema-Luiting

Publisher

Elsevier BV

Related search

Alectinib in Untreated Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer

Annals of Translational Medicine

English

Diagnostic Assays for Identification of Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer

Cancer Research

English

Clinical Challenges in Targeting Anaplastic Lymphoma Kinase in Advanced Non-Small Cell Lung Cancer

Cancer Chemotherapy and Pharmacology

Cancer Research

English

Expanding Anaplastic Lymphoma Kinase Therapeutic Indication to Early Stage Non-Small Cell Lung Cancer

Translational Lung Cancer Research

English

P1.15-16 ALKConnect: An Anaplastic Lymphoma Kinase Positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Patient Insights Network

Journal of Thoracic Oncology

Respiratory Medicine

English

Anaplastic Lymphoma Kinase (ALK) Inhibitors for Second-Line Therapy of Non-Small Cell Lung Cancer

Lung Cancer: Targets and Therapy

English

P3.01-30 Treatment Sequencing in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC) in Japan

Journal of Thoracic Oncology

Respiratory Medicine

English

Are Anaplastic Lymphoma Kinase Gene Rearrangements in Non-Small Cell Lung Cancer Prognostic, Predictive, or Both?

Journal of Thoracic Oncology

Respiratory Medicine

English

Pcn198 - An Economic Systematic Literature Review (Slr) for Anaplastic Lymphoma Kinase-Positive (Alk+) Non-Small-Cell Lung Cancer (Nsclc)

Value in Health

Occupational Health

English